Liver Fibrosis in Metabolic Dysfunction: Cellular and Molecular Mechanisms, Innovative Diagnostics, and Emerging Therapeutic Approaches
Contents
Chair
Prof. Ralf Weiskirchen
The head of the Institute of Molecular Pathobiochemistry, Experimental Gene Therapy, and Clinical Chemistry (IFMPEGKC) at the RWTH University Hospital Aachen, Germany
Scientific Secretariat
Prof. Amedeo Lonardo
Editor-in-Chief of Metabolism and Target Organ Damage
Moderator
Assoc. Prof. Gyorgy Baffy
- Department of Medicine, VA Boston Healthcare System and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
- Associate Professor of Medicine at Harvard Medical School and Chief of Gastroenterology at the VA Boston Healthcare System, Boston, MA, USA
Speaker(s)
Prof. Wolfgang Stremmel
Medical Center Baden-Baden, Baden-Baden, Germany
Dr. Mohamad Jamalinia
Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Iran
Prof. Alessandro Mantovani
Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy
Dr. Shelley Keating
School of Human Movement and Nutrition Sciences, The University of Queensland, Brisbane, Australia
Asst. Prof. Thomas Jensen
- University of Colorado Department of Medicine, Division of Endocrinology, Denver, CO, USA
- Director of Diabetes and Metabolic Medicine for Transplant and Co-Director of NAFLD Multidisciplinary Clinics
Programme
Programme
| Time (GMT-2, Germany) | Chair/Moderator/Speakers | Topic |
| 04:00 PM - 04:10 PM | Ralf Weiskirchen | Introduction: etiology, burden and clinical spectrum of liver fibrosis |
| Session 1 – Pathobiology and diagnosis | ||
| 04:10 PM - 04:25 PM | Wolfgang Stremmel | Low phosphatidylcholine in biliary mucus as pathogenetic factor in primary sclerosing cholangitis (PSC), the genuine fibrotic disease of the biliary tract? |
| Session 2 – Clinical spectrum | ||
| 04:25 PM - 04:40 PM | Mohamad Jamalinia | Impact of Liver Fibrosis on Cardiovascular Risk: Prognostic Insights and Limitations |
| 04:40 PM - 04:55 PM | Alessandro Mantovani | Role of Liver Fibrosis in the Progression of Chronic Kidney Disease |
| Session 3 – Management options | ||
| 04:55 PM - 05:10 PM | Shelley Keating | Exercise for Fibrosis/Fibroinflammation in MASLD |
| 05:10 PM - 05:25 PM | Thomas Jensen | Drug treatment of liver fibrosis |
| Session 4 – Presentation of the Journal, general discussion, and concluding remarks | ||
| 05:25 PM - 05:35 PM | Gyorgy Baffy | Presentation of M&TOD |
| 05:35 PM - 05:50 PM | Gyorgy Baffy | Q&A |
| 05:50 PM - 06:00 PM | Ralf Weiskirchen | Concluding remarks |
Relevant Special Issue(s)
Topic: Liver Fibrosis in Metabolic Dysfunction: Cellular and Molecular Mechanisms, Innovative Diagnostics, and Emerging Therapeutic Approaches
https://www.oaepublish.com/specials/mtod.2034Moments
Presentation
NaN
NaN
NaN
NaN
NaN
NaN
NaN
NaN
